Harvard biotech wiz Greg Verdine grabs a $55M A round to build a groundbreaking biotech
It’s hard not to enjoy talking with Greg Verdine about the new biotech companies he sets up. Years of teaching at Harvard have honed his skill for translating science into a pithy set of stories that everyone can understand and get a kick out of.
“What I am really passionate about is discovering new types of molecules that do things that can’t be done by standard small molecules and antibodies,” he told me in the lead-up to today’s formal launch of LifeMine Therapeutics with a $55 million A round. “I want to go after undruggable targets, get drugs that people consider now aren’t doable. The question is where you go looking for this.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.